ArticleScientific reports2025
Association of different treatment modalities for rectal cancer and second primary urinary system neoplasms, findings from SEER.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the risk of secondary primary urinary system neoplasms (SPUNs) in patients undergoing different treatment strategies during the perioperative period of rectal cancer (RC) and evalue survial prognostsis of SPUNs. The data were sourced from the US SEER database from 1975 to 2020. A total of 85,799 RC patients who underwent surgical treatment were included and divided into four groups: surgery alone (S), surgery plus chemoradiotherapy (SCR), surgery plus radiotherapy (SR), and surgery plus chemotherapy (SC). The results showed significant differences in the cumulative incidence of SPUNs among the four groups, with higher rates in patients receiving radiotherapy and chemotherapy. Both chemotherapy and radiotherapy increased the incidence of secondary primary bladder cancer (SPBC), and radiotherapy also elevated the incidence of secondary primary urethral cancer (SPUaC). However, there was no obvious association between chemoradiotherapy and the incidence of secondary primary kidney cancer (SPKC) or secondary primary ureteral cancer (SPUrC). Risk analysis indicated that the independent risk factors for SPBC were age, year of diagnosis, and postoperative radiotherapy, while race was a protective factor. For SPKC, the independent risk factors were age and year of diagnosis. No significant influencing factors were found for SPUrC, and postoperative radiotherapy was an independent risk factor for SPUaC. The relative risk (RR) of SPBC increased with the prolongation of the latency period after chemoradiotherapy. The RR value of radiotherapy was related to the year of diagnosis, reaching the highest from 1975 to 1984, and was the highest in the 18-50 age group after radiotherapy. Survival analysis revealed differences in cancer-specific survival (CSS) and overall survival (OS) among the four groups, with lower survival rates in patients receiving postoperative radiotherapy. After propensity score matching (PSM), only the overall survival rate of SPUNs patients in the postoperative radiotherapy group was lower than that of patients with original primary urological neoplasms (OPUNs). In conclusion, chemoradiotherapy during the perioperative period of RC is associated with the risk of SPUNs, and its benefits and risks need to be weighed in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.